Silver Book Fact

Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.

Chestnut, Charles H., Arne Skag, Claus Christiansen, Robert Recker, Jacob A. Stakkestad, Arne Hoiseth, Dieter Felsenberg, Hermann Huss, Jennifer Gilbride, Ralph C. Schimmer, and Pierre D. Delmas. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis. J Bone Miner Res. 2004; 19(8): 1241-9. http://www.ncbi.nlm.nih.gov/pubmed/15231010

Reference

Title
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Publication
J Bone Miner Res
Publication Date
2004
Authors
Chestnut, Charles H., Arne Skag, Claus Christiansen, Robert Recker, Jacob A. Stakkestad, Arne Hoiseth, Dieter Felsenberg, Hermann Huss, Jennifer Gilbride, Ralph C. Schimmer, and Pierre D. Delmas
Volume & Issue
Volume 19, Issue 8
Pages
1241-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.  
  • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…  
  • Reducing secondary bone fractures can reduce medicare spending
    Reducing 5-20 percent of “secondary” bone fractures in 2015 could have reduced Medicare FFS spending by $310 million to $1.2 billion over a follow-up period that lasted up to 2 to…